BC Week In Review | Sep 28, 2015
Clinical News

PXS4728A: Phase Ib data

Data from 24 healthy volunteers in the Phase Ib portion of the double-blind, placebo-controlled, Australian Phase Ia/Ib PXS-4728A-101 trial showed that once-daily 3-10 mg oral PSX-4728A for 14 days were well tolerated. Pharmaxis previously reported...
BC Week In Review | May 25, 2015
Company News

Pharmaxis, Boehringer Ingelheim deal

Boehringer exercised its option to acquire worldwide rights to anti-inflammatory candidate PXS4728A and related molecules from Pharmaxis. Boehringer plans to develop the oral vascular adhesion protein-1 (VAP-1; SSAO) inhibitor to treat nonalcoholic steatohepatitis (NASH). The...
BC Extra | May 19, 2015
Company News

Boehringer acquires Pharmaxis' NASH candidate

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised its option to acquire global rights to anti-inflammatory candidate PXS4728A and related molecules from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY). Boehringer plans to develop the oral vascular adhesion protein-1 (VAP-1; SSAO)...
BC Week In Review | Apr 13, 2015
Clinical News

PXS4728A: Interim Phase I data

Interim data from 48 healthy volunteers in the double-blind, placebo-controlled, Australian Phase I PXS-4728A-101 trial showed that single doses of 1-20 mg oral PXS4728A led to no safety concerns. Data from the single ascending-dose portion...
BC Week In Review | Mar 16, 2015
Company News

Pharmaxis, Boehringer Ingelheim deal

Boehringer Ingelheim received an exclusive option to license worldwide rights to Pharmaxis’ PXS4728A and related molecules. Pharmaxis will receive EUR1.3 million ($1.4 million) for the option, which expires on May 15. PXS4728A, an oral vascular...
BC Extra | Mar 14, 2015
Company News

Boehringer eyeing NASH space with Pharmaxis option

Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire worldwide rights to PXS4728A . According to Pharmaxis, Boehringer is interested in developing the compound to treat non-alcoholic steatohepatitis (NASH). The...
BC Week In Review | Feb 2, 2015
Clinical News

PXS4728A: Phase I started

Pharmaxis began the double-blind, placebo-controlled, Australian Phase I PXS-4728A-101 trial to evaluate single and multiple ascending doses of oral PXS4728A in about 72 healthy male volunteers ages 18-60. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia...
Items per page:
1 - 7 of 7